Notice NOT-OD-24-015 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-DK-25-002 from the NIH Guide for Grants and Contracts. This Notice of Funding Opportunity (NOFO) invites cooperative agreement applications to expand the operational scope of the existing Human Pancreas Analysis Program (HPAP) to the study of pancreata recovered from tissue donors with Type 2 Diabetes (T2D) and related metabolic disorders. This NOFO will support one team of investigators with combined expertise in human pancreas physiology and pathophysiology; collection, processing and multimodal analysis of human pancreatic tissues; and biological database building, curation and management, that will be tasked to: 1) identify, collect and intensively characterize primary pancreatic tissues from patients with T2D and related forms of islet dysfunction, as well as age-matched controls; and 2) analyze, organize and share the data resulting from the study of these tissues through use and expansion of the existing PANC DB open-access resource database. HPAP is a component of the Human Islet Research Network (HIRN), created in 2014 to support innovative and collaborative translational research to understand how human beta cells are lost in Type 1 Diabetes (T1D), and to find innovative strategies to protect and replace functional human beta cell mass.

Notice NOT-CA-24-005 from the NIH Guide for Grants and Contracts

Notice NOT-OD-24-016 from the NIH Guide for Grants and Contracts

Notice NOT-DE-24-003 from the NIH Guide for Grants and Contracts

Notice NOT-CA-24-004 from the NIH Guide for Grants and Contracts

Notice NOT-AG-23-068 from the NIH Guide for Grants and Contracts

Notice NOT-OH-24-001 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-24-046 from the NIH Guide for Grants and Contracts. The National Institutes of Health (NIH) Tackling Acquisition of Language in Kids (TALK) initiative seeks to support activities to better understand early language learning and delay. NIH TALK invites applications for research projects that aim to better understand the information and practice needs of caregivers, professionals, and other invested parties who support late talking children and to determine whether those needs are being effectively met. Community engaged research combined with rigorous qualitative research and diverse perspectives is needed to enrich our understanding of how to get state-of-the-science information and practice to those who need it most to guide decisions about late talking children.

Notice NOT-AG-23-067 from the NIH Guide for Grants and Contracts

Notice NOT-RM-23-026 from the NIH Guide for Grants and Contracts

Notice NOT-DK-24-001 from the NIH Guide for Grants and Contracts

Notice NOT-NS-24-026 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-24-051 from the NIH Guide for Grants and Contracts. The NIDCD is committed to identifying effective interventions for the diagnosis, prevention, or treatment of communication disorders by supporting well-designed and well-executed clinical trials. This funding opportunity announcement (FOA) supports investigator initiated low risk clinical trials addressing the mission and research interests of NIDCD. Clinical trials must meet ALL the following criteria: meet the budget limits of this FOA, not require FDA oversight, are not intended to formally establish efficacy and have low risks to potentially cause physical or psychological harm.

Funding Opportunity PAR-24-050 from the NIH Guide for Grants and Contracts. he NIDCD is committed to identifying effective interventions for the treatment or prevention of communication disorders by supporting well designed and well executed clinical trials. This funding opportunity announcement (FOA) supports a cooperative agreement between an NIDCD Project Scientist and an investigator to support a clinical trial that meets ANY of the following criteria: requires FDA oversight, is intended to formally establish efficacy, or has a higher risk to potentially cause physical or psychological harm.

Funding Opportunity RFA-AG-24-040 from the NIH Guide for Grants and Contracts. This Notice of Funding Opportunity (NOFO) invites U54 Cooperative Agreement applications aiming to establish multi-component Alzheimers Disease and Related Dementias Translational Centers for Microphysiological Systems (MPS) (AD/ADRD MPS Translational Centers). The overarching purpose of this Centers program is to develop 2D and 3D models of AD/ADRD as reproducible and scalable platforms that recapitulate key features of human AD/ADRD pathophysiology to be used as precision medicine research tools to investigate the complex biology of AD/ADRD and to accelerate multiple aspects of drug discovery and preclinical drug development.

Notice NOT-HL-23-117 from the NIH Guide for Grants and Contracts

Notice NOT-AG-23-066 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-NS-24-013 from the NIH Guide for Grants and Contracts. This RFA will solicit applications for a pivotal phase 3 clinical trial to determine the efficacy of FDA approved monoclonal antibody therapy compared to placebo in diverse "mixed dementia" populations with a focus on vascular contributions. Mixed dementia refers to dementia cases positive for 1) Alzheimer biomarkers, such as amyloid positron emission tomography and/or low cerebrospinal fluid amyloid beta 42 combined with elevated phosphorylated tau; and 2) evidence of vascular contributions based on imaging (white matter disease and/or subclinical infarction). Bayesian approaches with response adaptive randomization to examine specific subgroups are engouraged. Successful applications will be well-powered to determine efficacy in diverse populations representative of the effect of the disease in the United States by sex, race/ethnicity, and geographic distribution. Applications must include patient and community engagement cores that are incorporated into all stages of program development and at all levels of the organizational structure.

Notice NOT-DA-23-039 from the NIH Guide for Grants and Contracts